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Abstract
Interferons (IFNs) with antiviral and immune-stimulatory functions have been widely used in prevention and treatment of
hepatocellular carcinoma (HCC). Signal transducer and activator of transcription 1 (STAT1) is a key element of the IFN
signaling, and the function of STAT1 is critically determined by its phosphorylation state. This study aims to understand the
functions of phosphorylated (p-) and unphosphorylated (u-) STAT1 in HCC. We found that u-STAT1 is significantly elevated in
patient HCC tumor tissues and predominantly expressed in cytoplasm; while p-STAT1 is absent. Loss of u-STAT1 potently
arrested cell cycle and inhibited cell growth in HCC cells. Induction of p-STAT1 by IFN-α treatment effectively triggers the
expression of interferon-stimulated genes (ISGs), but has moderate effect on HCC cell growth. Interestingly, both u-STAT1 and
p-STAT1 are induced by IFN-α, through with distinct time-dependent process. Furthermore, the ISG induction patterns mediated
by p-STAT1 and u-STAT1 are also distinct. Importantly, artificial blocking of the induction of u-STAT1, but not p-STAT1,
sensitizes HCC cells to treatment of IFNs. Therefore, p-STAT1 and u-STAT1 exert dichotomal functions and coordinately
regulate the responsiveness to IFN treatment in HCC.
Key Messages
& STAT1 is upregulated and predominantly presented as u-STAT1 in HCC, while p-STAT1 is absent.
& U-STAT1 sustains but p-STAT1 inhibits HCC growth.
& The dynamic change of phosphorylation state of STAT1 control the responsiveness to IFN treatment.
Keywords Hepatocellular carcinoma (HCC) . Signal transducer and activator of transcription 1 (STAT1) . Interferon (IFN)
signaling . Immune response
Introduction
Hepatocellular carcinoma (HCC) is one of the most common
malignant tumors [1] and the second leading cause of cancer-
related death worldwide [2]. As a major etiology, chronic in-
fection with hepatitis B or C virus (HBV or HCV) triggers
liver fibrosis, cirrhosis, and eventually the development of
HCC [3]. To prevent from or treat for viral hepatitis-related
HCC, interferons (IFNs) have been explored in clinic [4, 5]. In
context of tumors, IFNs can be produced by various cell types,
including immune cells, as well as tumor cells. They elicit
antitumor effects by directly controlling tumor cells or indi-
rectly by regulating immune response [6]. On the contrary, the
pro-tumorigenic effect of IFNs, which may help the tumor
escape the recognition of the immune system through
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Bimmunoediting,^ has also been reported [7, 8]. However,
which side wins the tussle appears to be dependent on the
context of tumor type, microenvironmental factors, and sig-
naling intensity [7]. But the exact mechanisms remain poorly
understood due to their multitude functions in respect to both
intra-tumoral and micro-environmental determinants [9].
Although benefits of reducing cancer risk have been observed
in clinical studies [5], IFN treatment for the management of
HCC is still controversial and no clear recommendations have
been proposed [9].
Signal transducer and activator of transcription 1 (STAT1),
an important upstream regulator of the IFN signaling, func-
tions as the core transcription factor to drive the transcription
of a subset of IFN-regulated genes (IRGs) [10]. Upon IFN
stimulation, phospho-STAT1 (p-STAT1) acts as a key element
for STAT1 homodimerization (STAT1-STAT1) or
heterodimerization (STAT1-STAT2-IRF9 complex, ISGF3).
These complexes translocate to the nuclear with subsequent
binding to interferon-stimulated response elements (ISRE)
and interferon-gamma activated sequences (GAS), and then
stimulate the transcription of IRGs to regulate host immune
response and cell growth [11]. Although STAT1 has been
found to be deregulated in a variety of cancers, the exact role
of STAT1 in cancer, especially in different types of cells, re-
mains controversial. On one hand, STAT1 is recognized as a
tumor suppressor which can inhibit tumor growth through
regulating cell proliferation, differentiation, and death
[12–15]. On the other hand, STAT1 can also be a tumor pro-
moter as it can promote tumor cell growth, therapy resistance,
and immune suppression [16, 17]. In addition, expression of
STAT1 has been found to correlate with both good and poor
prognosis in different types of cancers [8]. Although STAT1
was reported to be a potential suppressor in HCC [18], the
findings are based on limited numbers of patients and a mod-
est effect on HCC cell growth.
Upon IFN stimulation, p-STAT1 and unphospho-STAT1
(u-STAT1) act as two forms of STAT1 to perform its function
[19]. Although p-STAT1 is recognized as the key activator of
IFN signaling, u-STAT1 can also regulate gene transcription
in the absence of IFN stimulation [20]. Thus, p-STAT1 and u-
STAT1 stimulate transcription of different subsets of genes,
which have distinct functions in immune responses of tumors
to IFN-related therapy [9]. A subset of ISGs with pro-
apoptotic and anti-proliferative functions have been identified
to be stimulated by STAT1 during IFN treatment, through
which regulate tumor growth [21–23]. Furthermore, immune
effector cells can also be activated by IFNs and recruited into
tissues, which may augment the anti-tumor effects by induc-
ing apoptosis of the target cells. In contrast, chronic exposure
of cells to low IFNs under pathological conditions may steadi-
ly induce expression of ISGs that are controlled by u-STAT1,
denoted as IFN-related DNA damage resistance signature
(IRDS), which can promote tumor growth and metastasis
[24]. Therefore, p-STAT1 and u-STAT1 were thought to have
distinct functions and have been used as independent prog-
nostic markers in predicting disease outcomes in cancer [25].
In this study, we investigated the expression and functions
of p-STAT1 and u-STAT1 in HCC. Remarkably, we found that
STAT1 was predominantly present as u-STAT1 form and was
highly expressed in the cytoplasm of tumor cells from HCC
patients. Although p-STAT1 induced by IFN-α treatment ro-
bustly stimulated ISG expression by activating the IFN sig-
naling pathway and inhibited HCC growth, its function was
quickly blocked by intrinsic or induced u-STAT1. Thus, the
tumor-suppressive or tumor-promoting role of STAT1 largely
depends on its phosphorylation status. The dynamic induction
of p-STAT1 and u-STAT1 by IFN treatment coordinately reg-
ulates the growth of tumor cells.
Material and methods
Tissue microarray
Archived formalin fixed paraffin-embedded tissue samples
from 133 patients who underwent hepatic resection for HCC
at Erasmus MC-University Medical Center between 2004
and 2014 were used for this study. Clinical data of this HCC
cohort have been published previously [26]. The use of pa-
tient materials was approved by the medical ethical commit-
tee of Erasmus MC. Tissue microarray (TMA) slides
contained three or four 0.6-mm cores from the tumorous
area and two 0.6-mm cores from the paired tumor-free liver
(TFL) area of these patients.
Quantitative real-time polymerase chain reaction
Cells were washed with PBS for two times in indicated time
and cell lysates were prepared. RNA was isolated using a
Fig. 1 STAT1 expression is upregulated in tumors of HCC patients. aThe
Oncomine microarray database (https://www.oncomine.org) was
searched to analyze mRNA expression of STAT1 in HCC patients. In
total, five cohorts of 424 HCC tumor tissues compared with 346 paired
tumor-free tissues from the same patients were identified. STAT1 mRNA
was significantly upregulated in tumor tissues compared with tumor-free
tissues in four of the five cohorts, P < 0.001. b STAT1 expression profile
across 486 patient samples including 247 HCC tumors and 239 tumor-
free liver tissues (including 186 paired samples) derived from GEO
Datasets (GSE 14520). STAT1 mRNA expression was significantly
higher in tumor tissues comparing with tumor-free tissues (mean ± SD,
***P < 0.001). c Landscape of all the online cohorts. d Cytoplasmic
STAT1 was significantly upregulated in HCC tumors. The cytoplasmic
STAT1 protein immune-reactivity scores (IRS), obtained by multiplying
the scores for proportions of stained cells and the scores for expression
intensity, range from low (score 0–3), moderate (score 3–6), and high
(score 6–9) (mean ± SEM, n = 133, **P < 0.01). d No significant
difference was found in nuclear STAT1 expression IRS scores (mean ±
SEM, n = 133, ns, no significant)
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Machery-NucleoSpin RNA II kit (Bioke, Leiden,
Netherlands) and quantified using a Nanodrop ND-1000
(Wilmington, DE, USA). RNA (500 ng) was employed to
make cDNA using a cDNA Synthesis Kit (Takara BIO
J Mol Med
INC). SYBRGreen-based real-time PCR (MJ Research
Opticon, Hercules, CA, USA) was used to amplify the target
genes. The program was set as 95 °C for 10 min; 40 cycles at
95 °C for 15 s and at 58 °C for 30 s according to the manu-
facturer’s instructions. GAPDH was considered as reference
gene to normalize target gene expression. Human primer se-
quences used for qPCR are included in Table S1.
Statistical analysis
Statistical analysis was performed by using the nonparametric
Mann–Whitney test for paired or non-paired data, or the
paired t test using GraphPad InStat software as appropriate.
Crude (non-adjustment) survival analysis (Kaplan-Meier
curve) was first used to display the overall survival difference.
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Fig. 2 p-STAT1 is absent in both
HCC tumors and cell lines. a No
expression of p-STAT1 in HCC
tumors and tumor-free tissues.
Tumors (n = 32) and tumor-free
tissues (n = 19) were stained for p-
STAT1 (Y701). Paraffin-
embedded Hela cells treated with
IFNs were used as a positive
control. b Absence of p-STAT1 in
HCC cell lines. Cell lysates were
collected for Western blot, and
qRT-PCR was used to measure
the mRNA levels of STAT1
(mean ± SD, n = 3 independent
experiments, two biological
repeats for each)
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Hazard ratios (HRs) and 95% Cls were calculated to evaluate
the prognostic power of variables of patients. P value < 0.05
was considered statistically significant.
Results
STAT1 expression is elevated in tumor tissues
of hepatocellular carcinoma patients
In order to investigate STAT1 expression in HCC patients, we
first searched the online datasets from Oncomine and GEO
Datasets (GSE 14520), including six cohorts of 671 HCC tu-
mor tissues with 585 tumor-free liver tissues. To our surprise,
STAT1 mRNA expression was significantly upregulated in tu-
mors of five of the six cohorts (Fig. 1a–c). To further confirm
these results, TMA slides including tumor tissues and paired
tumor-free liver tissues of 133 HCC patients were stained for
STAT1. Positive staining of STAT1 in both nuclear and cyto-
plasm was found in most of the patients. Nuclear STAT1 is
often recognized as p-STAT1, while cytoplasmic STAT1 is re-
ferred as u-STAT1 [27]. Therefore, we scored the nuclear and
cytoplasm expression of STAT1 separately. Consistent with the
RNA expression data derived from the online datasets, cyto-
plasmic STAT1 protein expression in tumor tissues was signif-
icantly higher than that in tumor-free tissues (Fig. 1d), but no
difference in nuclear STAT1 expression between tumors and
tumor-free tissues was found (Fig. 1e).
Among all the clinical factors, alpha-fetoprotein (AFP) se-
rum level and tumor differentiation were significantly associ-
ated with higher patient mortality (Table S2). This result is
consistent with the general consensus that serum AFP is an
independent indicator for HCC prognosis [28]. Correlation of
STAT1 expression with clinical behavior were further ana-
lyzed. High cytoplasmic STAT1 was not significantly associ-
ated with the analyzed factors (Table S3). However, high nu-
clear STAT1 expression was significantly associated with pa-
tient age (Table S4). Furthermore, no significant correlation
was observed between STAT1 expression and patient survival
outcome (Fig. S1). Collectively, we found that cytoplasmic
STAT1 expression in tumor tissues appears higher compared
to tumor-free tissues.
p-STAT1 is absent in tumor tissues of hepatocellular
carcinoma patients and human hepatoma cell lines
As the key component of JAK-STATsignaling, STAT1 is phos-
phorylated after activation and then translocates to the nucleus.
Although u-STAT1 has been generally recognized as present in
cytoplasm, emerging evidence has indicated its translocation to
nuclei and its function as a transcription factor [29].
To clarify the phosphorylation status and localization of
STAT1, we stained TMA slides with tissues of 32 patients
with specific antibodies against phosphorylated STAT1.
Hela cells treated with IFNs were used as a positive control.
Surprisingly, we did not observe positive staining for p-
STAT1 in both tumor and tumor-free tissues (Fig. 2a).
Consistently, p-STAT1 was absent in all HCC cell lines,
whereas u-STAT1 was highly expressed (Fig. 2b). Thus,
we have demonstrated that STAT1 is predominantly present
in unphosphorylated state in HCC tissues and human hepa-
toma cell lines.
Knockout of u-STAT1 impairs hepatocellular
carcinoma cell growth
To determine the functions of u-STAT1, we generated u-STAT1
knockout cells by Lenti-CRISPR/Cas9 system in Huh7 and
Huh6 HCC cell lines (Fig. S2). Complete loss of STAT1 was
demonstrated at protein level by western blot analysis (Fig. 3a).
Finally, three wild-type and three knockout clones of both cell
lines were selected for subsequent experimentation. The colony
formation unit (CFU) assay measures the ability of single cells
to form clones. Strikingly, we observed that knockout of u-
STAT1 inhibited CFU formation of HCC cells (Fig. 3b), in
contrast to previous findings that STAT1 served as a tumor
suppressor [18, 25]. Cell cycle analysis revealed that loss of
u-STAT1 significantly increased the proportion of Huh7 and
Huh6 cells in the G1 phase and concomitantly decreased the
proportion of cells in S-phase (Fig. 3c). These data suggest that
u-STAT1 sustains HCC cell growth.
Activation of STAT1 phosphorylation by IFN-α
treatment hardly inhibits hepatocellular carcinoma
cell growth
As the active form of STAT1, p-STAT1 has been widely recog-
nized as the functional form in inhibiting tumor growth through
inducing cell apoptosis and regulating cell cycle [8, 21].
Because p-STAT1 is absent in HCC cells, IFN-αwas employed
to activate STAT1 phosphorylation. Upon IFN-α treatment, p-
STAT1 was strongly induced in Huh7 and Huh6 cells, but not
in STAT1 knockout cells (Fig. 4a). Huh7 and Huh6 with or
without STAT1 were treated with different concentrations of
IFN-α. Surprisingly, both cells lines were resistant to IFN-α
treatment on cell proliferation, although Huh7 cells showed
modest growth inhibition. Furthermore, no significant differ-
ence of cell growth between STAT1 knockout cells and WT
controls was observed (Fig. 4a). Consistent to the MTT results,
only Huh7 cells showed a slight inhibition on colony formation
and no difference was found between knockout andWTcells in
both cell lines (Fig. 4b).
Induction of ISGs is the hallmark of STAT1 activation [30].
As expected, a subset of ISGs were strongly induced by
IFN-α treatment, while the stimulation was abolished in
STAT1 knockout cells (Fig. 5a). Besides, the difference of
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Fig. 3 Knockout of u-STAT1 inhibits HCC cell growth. a Knockout of
STAT1 inHCC cell lines. Cell lysates fromHuh7 andHuh6 clones transduced
with LentiCRISPR/Cas9 vector were collected for western blot.β-actin served
as loading control. b U-STAT1 knockout significantly inhibited the colony
formation of Huh7 and Huh6 cell lines, as measured by clone size (mean ±
SD, n= 27, ***P< 0.001; **P< 0.01). c U-STAT1 knockout arrested cell
cycling. U-STAT1 knockout arrested Huh7 and Huh6 cells in G1 phase deter-
mined by flow cytometric analysis (mean ± SD, n=9. **P< 0.01)
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gene regulations between p-STAT1 and u-STAT1 were further
compared. ISGs with pro-apoptotic functions, such as FAS,
TRAIL, were found only regulated by p-STAT1 during IFN
stimulation (Fig. 5b, c). ISGs of the IRDS members that are
known to promote tumor growth and metastasis are regulated
by u-STAT1 (Fig. 5d, e). However, we failed to observe the
apoptosis induction of IFN-α in HCC cells, while TNF-α did
in Huh6 cells (Fig. 5f). In addition, IFN-α also did not show
synergistic effect with TNF-α in apoptosis induction. These
results suggest that HCC cells are resistant to growth regula-
tion by IFN-α treatment, although p-STAT1 and ISGs with
pro-apoptotic functions are robustly activated.
U-STAT1 serves as a feedback loop to block
the inhibitory effect of p-STAT1 on hepatocellular
carcinoma cell growth
To understand why HCC cells are insensitive to IFN-α treat-
ment, we profiled the dynamic change of p-STAT1 and u-
STAT1 expression. In fact, STAT1 is one of the most impor-
tant ISGs. Both p-STAT1 and u-STAT1 were strongly induced
by IFN-α. P-STAT1 peaked at 0.5 h after IFN-α treatment and
thereafter decreased gradually, whereas u-STAT1 started to
gradually increase 8 h post-treatment (Fig. 6a). The expression
of JAK1 was not changed, which has been demonstrated to be
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Fig. 4 IFN-α exerts modest inhibition on HCC cells independent of p-
STAT1. a IFN-α treatment did not or only modestly inhibit HCC cell
growth independent of p-STAT1. Huh7 and Huh6 cells were treated by
IFN-α (1000, 5000 and 10,000 IU/ml) for 7 days, and cell growth was
determined by MTT assay (mean ± SD, n = 4 independent experiments
with triplicates for each). p-STAT1wasmeasured bywestern blot andwas
strongly stimulated by treatment of IFN-α (1000 IU/ml) for 30 min. b
IFN-α (1000 IU/ml) modestly inhibited the colony formation. Clone size
of IFN-α untreated HCC cells were normalized to treated cells, and data
were present as STAT1 KO cells comparing with controls (CTR) (mean ±
SD, n = 3, ns, not significant)
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inhibited by u-STAT1 [19]. We hypothesize these two forms
may antagonize each other, and eventually deters the response
to IFN-α treatment.
To dissect these complicated interactions, we artificially con-
trol STAT1 expression by genome modification. We
exogenously expressed CMV promotor controlled WT
(Huh6-KO-WT) or mutant (Y701F) (Huh6-KO-Y701F)
STAT1 in STAT1 knockout Huh6 cells. Thus, STAT1 mRNA
was constitutively expressed driven by the exogenous CMV
promoter and therefore no longer be induced by IFN-α.
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Treatment of IFN-α activated p-STAT1, but the expression of
u-STAT1 was no longer induced in these cells (Fig. 6a). As
expected, ISG expression was strongly induced by IFN-α by
re-expressing STAT1 in knockout cells, although no major ef-
fect on the basal expression of ISGs (Fig. S3). Importantly, both
the colony formation and MTT assays show that blocking the
induction of u-STAT1 expression sensitized Huh6-KO-WT
cells to IFN-α/γ treatment. In contrast, this effect was not ob-
served in Huh6-KO-Y701F, in which STAT1 cannot be phos-
phorylated, indicating the requirement of p-STAT1 activation
for IFN-α/γ function (Fig. 6b). Even though STAT1 is impor-
tant for sustaining the HCC cell growth, restoration of u-STAT1
expression in Huh6 knockout cells did not promote HCC
growth (Fig. S4). Furthermore, by blocking u-STAT1 induc-
tion, both cleaved caspase-3 and p21 expression were stimulat-
ed in Huh6-KO-WTcells, but decreased in Huh6 cells (Fig. 6c).
These results suggest that the induction of u-STAT1 as a feed-
back loop antagonizes the function of p-STAT1 and protects
HCC cells from IFN-α treatment.
Discussion
As the key component of IFN signaling, STAT1 have been
reported with both pro- and anti-tumor functions during
cancer development from clinical studies in cancer patients
[8]. Deregulated expression of STAT1 has been observed in
a variety of cancer types [31–34]. It is closely correlated to
clinical behaviors of patients, either good or poor prognosis
[16, 33]. In HCC, the expression of STAT1 has been report-
ed to be lower in tumor tissues and is negatively associated
with the histological grade [18]. However, we found that
expression of STAT1 is higher in HCC tumor tissues in both
our patients and other cohorts from online datasets,
consisting of a large number of patients. Compared to the
tumor-free tissues, we found higher levels of STAT1 is in the
cytoplasm of HCC cells, whereas the levels in nuclear are
comparable. The exact reasons accounting for the discrep-
ancy between our results and the previous studies remain to
be further investigated [18].
The phosphorylation status is essential for the functions of
STAT1. In general, p-STAT1 is supposed to locate in nuclear,
while u-STAT1 is considered predominately present in cyto-
plasm [27]. Surprisingly, we found that p-STAT1 is completely
absent in our HCC tumor tissues and HCC cell lines, indicating
that u-STAT1 is the dominant form located in both nuclear and
cytoplasm. This is consistent with previous finding that u-
STAT1 can shuttle between cytoplasm and nuclear and rein-
forces host defense against viral infection [29]. However, the
expression levels of STAT1 in either nuclear or cytoplasm are
not significantly related to survival in our patients.
Experimental studies in STAT1 knockoutmouse have dem-
onstrated a tumor suppressor function mainly through tumor
intrinsic and extrinsic mechanisms [17, 35]. Cell cycle regu-
lator, apoptosis inducers, and genes of immune system have
been recognized as downstream targets of STAT1. However,
several oncogenes have been reported to be regulated by
STAT1, which are involved in promotion of tumor growth
and invasiveness, suppression of immune surveillance, and
induction of therapy resistance [8]. Thus, STAT1 plays multi-
faceted roles in cancer development. In HCC, we found that
silencing u-STAT1 inhibits cell growth and arrests cell cycle,
indicating u-STAT1 sustains the growth of HCC.
Furthermore, ISGs recognized as IRDS were selectively reg-
ulated by u-STAT1, which may lead to resistance to DNA
damage. These results are partially consistent with previous
finding that u-STAT1 can protect tumor cells from apoptosis
stimuli, radio- and chemotherapy [27, 34, 36, 37].
The classically active form of STAT1, p-STAT1, is strongly
induced during immune response and rapidly regulates down-
stream gene expression. It has been demonstrated that p-
STAT1 remarkably arrests tumor cell growth [23, 38, 39]. In
line with this, we found that p-STAT1 inhibits HCC cell
growth by arresting cell cycle and inducing cell apoptosis.
ISGs with pro-apoptotic functions, such as FAS, TRAIL are
Fig. 6 u-STAT1 works as a feedback loop in blocking p-STAT1 function.
a IFN-α treatment induced u-STAT1 and p-STAT1 expression.
Expressions of u-STAT1 and p-STAT1 were both induced in Huh7 and
Huh6 cells by IFN-α but not in Huh6-KO-WT determined by western
blot and qRT-PCR (mean ± SD, n = 4, *P < 0.05). bAttenuating u-STAT1
expression sensitized Huh6 cell to IFN treatment. Huh6-KO-WT and
Huh6-KO-Y701F cells were treated with IFN-α (1000 IU/ml) or IFN-γ
(1000 ng/ml). Decreased colony formation efficiency was found in Huh6-
KO-WTand also cell growth inhibition but not in Huh6-KO-Y701F cells
determined by MTT assay (mean ± SD, n = 3, **P < 0.01). c Blocking
IFN-α-induced u-STAT1 expression sensitized HCC cells to apoptosis
and cell cycle arrest. Cell lysates of Huh6 cells and Huh6-KO-WT treated
with IFN-α (1000 IU/ml) or IFN-γ (1000 ng/ml) were collected for west-
ern blot analysis. β-actin served as loading control
Fig. 5 SimplePara>STAT1 is the key component for IFN-α-induced ISG
expression but not for cell apoptosis. a STAT1 knockout abolished the
induction of ISGs by IFN-α. Huh6 KO and Huh7 KO cells were treated
with IFN-α (1000 IU/ml) for 24 h. ISG expression was determined by
qRT-PCR (mean ± SD, n = 3, two biological replicates for each indepen-
dent experiment, *P < 0.05; **P < 0.01; ***P < 0.001). b, c p-STAT1
strongly induced the expression of different ISGs. Huh6 and huh7 cells
were treated with IFN-α for 4 h. ISGs were quantified by qRT-PCR
(mean ± SD, n = 4, *P < 0.05; **P < 0.01; ***P < 0.001). c, d u-STAT1
regulates IRDS genes but not pro-apoptotic ISGs. The expression of ISGs
was compared between control and knockout cells in huh6 and huh7 by
qRT-PCR (mean ± SD, n = 4, *P < 0.05; **P < 0.01; ***P < 0.001). f
HCC cell lines are resistant to apoptosis induction by treatment of IFN-
α. Huh6 KO and Huh7 KO cells were treated with IFN-α (1000 IU/ml),
TNF-α (20 ng/ml), or the combination for 72 h. Cells were collected and
stained with Anexin V/PI, and subsequently analyzed by FACS (mean ±
SD, n ≥ 4, *P < 0.05, ns, not significant)
J Mol Med
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only regulated by p-STAT1 but not u-STAT1. However, p-
STAT1 is quickly dephosphorylated within only a few hours.
u-STAT1, which is transcribed by p-STAT1, subsequently
substitutes p-STAT1 expression and lasts for several days.
Consequently, the anti-tumor effect of p-STAT1 is attenuated
by the pro-tumor effect of u-STAT1. Thus, the function of
STAT1 is highly dependent on its phosphorylation state, and
p-STAT1 and u-STAT1 exert distinct functions.
IFNs have been widely explored for treating various
malignancies [6]. However, IFN monotherapy has limit-
ed efficacy, although combination of IFNs with other
tumoricidal therapies have been proven effective [40].
Systemic thermotherapy with IFNs for HCC has limited
benefit on patient survival and in some instances is
accompanied with significant toxicity [41], although an-
tiviral therapy with IFNs might reduce the risk of virus
infection in cancer patients [4]. Reasons for the clinical
failure of IFNs likely include inherent biological mech-
anisms, changes in cell population, and institution of
counter-regulatory pathways [42]. IFN signaling is gen-
erally considered to stimulate immune response, but it
has also been reported to induce immunosuppression
[9]. Different forms of STAT1, p-STAT1 and u-STAT1,
have shown different transcription properties that con-
tribute to the complexity of IFN signaling [9]. In our
study, we have demonstrated that p-STAT1 and u-
STAT1 play dual roles in HCC during IFN treatment.
These results may explain the possible mechanisms of
the ambiguous effects of IFNs in cancer treatment.
In summary, STAT1 is dominantly present as the form
of u-STAT1 in HCC cells. The phosphorylation state de-
ters the functions of STAT1 that u-STAT1 sustains but p-
STAT1 inhibits HCC growth. Upon IFN treatment, the
expression, phosphorylation, and localization of STAT1
are dynamically regulated and coordinately control the
responsiveness to IFN treatment. Thus, these findings pro-
vide mechanistic insight on the role of STAT1 in HCC
and provide scenario for future optimization of IFN
treatment.
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